Ru Wei Phd Email & Phone Number

Cambridge, Massachusetts, United States

Led proteomics, metabolomics technology, and bioinformatics development to support Biogen’s portfolio and exploratory programs and build drug discovery knowledgebases and tools. • Established metabolomics and lipidomics functions supporting biomarker discovery, pharmacodynamic assessment, and drug mode of action (MoA) evaluation for drug candidates targeting metabolite and lipid metabolism pathways underlying neurodegenerative diseases.• Built protein turnover database to advance novel therapeutic approaches via target degradation. • Supported neurodegenerative disease focused pipeline programs ranging from Lead ID to R2D.• Collaborated internal research and clinical development teams on multiple exploratory target projects.• Hired and managed a team of scientists specializing in Omics and bioinformatics since 2011.• Accountable for capital instrument acquisition and assisted function head manage budget and annual operating plan (AOP) since 2011.

Cambridge, Massachusetts, United States

Built a suite of proteomics technology platforms, including target engagement, selectivity and interaction measure, MoA investigation, and proteomics bioinformatics to support Biogen portfolio (2014 – 2020).• Led the development of various advanced proteomics technology platforms, including post-translational modification (PTM) proteomics, chemoproteomics, and protein turnover technology platforms.• Managed the evaluation and establishment of modern proximity labeling proteomics technologies, including BioID, TurboID and Miniturbo platforms.• Led development of iTRAQ, TMT and other labeling-based quantitative proteomics platforms, and affinity-based IP-MS interactome platform. • Supported kinase targeting and immune modulation pipeline programs (Lead ID to R2D).• Characterized multiple animal and cell models by using the proteomics platforms and built proteome databases to enhance drug discovery pipeline.• Established proteomics function to support pipeline programs for biomarker discovery, clinical patient stratification, and therapeutic target generation and validation (2011 – 2013). • Hired, coached, and managed a team of great proteomics scientists.• Acquired state-of-art mass spec instrumentation and built a lab. • Led development of various core proteomics technologies, including targeted proteomics, 2D-discovery proteomics, online Multi-Dimensional Protein Identification Technology (MudPIT) platform, and secretome platforms, and support portfolio programs.

Built and led the proteomics and metabolomics group to support biomarker discovery, clinical patient stratification, facilitate target generation and validation, and RNAi therapeutics.

Establishing Metabolomics platform

Phd, Analytical Chemistry And Kinetic Modeling

Master Of Science - Ms, Instrumental Analytical Chemistry